Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids.

ABSTRACT:

Background

Recurrence of retinoblastoma (RB) following chemoreduction is common and is often managed with local (intra-arterial/intravitreal) chemotherapy. However, some tumors are resistant to even local administration of maximum feasible drug dosages, or effective tumor control and globe preservation may be achieved at the cost of vision loss due to drug-induced retinal toxicity. The aim of this study was to identify drugs with improved antitumor activity and more favorable retinal toxicity profiles via screening of potentially repurposable FDA-approved drugs in patient-derived tumor organoids.

Methods

Genomic profiling of five RB organoids and the corresponding parental tissues was performed. RB organoids were screened with 133 FDA-approved drugs, and candidate drugs were

SUBMITTER: Srimongkol A 

PROVIDER: S-EPMC9890748 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature